SCM
KALV

Squadron Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Squadron Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-985,100
Closed -$19.8M – 52
2026
Q1 		$19.8M Buy
985,100
+285,100
+41% +$4.6M 7.27% 3
2025
Q4 		$11.3M Buy
+700,000
New +$9.27M 4.79% 5

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Squadron Capital Management's KALV Position: Q2 2026 in Review

Squadron Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 985,100 shares — an estimated $19.8M sold.

Squadron Capital Management first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $19.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Squadron Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 985,100 KalVista Pharmaceuticals shares in Q2 2026, an estimated $19.8M.
  • Squadron Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Squadron Capital Management's KalVista Pharmaceuticals position peaked at $19.8M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.